Cetuximab (weekly), CISSplatin 100mg/m² and 5-Fluorouracil 1000mg/m²/day Therapy - 21 day cycle

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locally advanced or metastatic squamous cell carcinoma of the head and neck</td>
<td>C76</td>
<td>00417a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

*If the reimbursement status is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Cetuximab is administered once weekly on days 1, 8 and 15, CISSplatin is administered on Day 1 and 5-Fluorouracil is administered on days 1-4 of a 21 day cycle for up to 6 cycles until disease progression or unacceptable toxicity develops.

Chemotherapy must not be administered earlier than 1 hour after the end of the cetuximab infusion.

**Maintenance cetuximab may be considered following the end of this treatment as per regimen 00207 Cetuximab Monotherapy-7 days**

Availability of resuscitation equipment MUST be ensured while administering cetuximab.

<table>
<thead>
<tr>
<th>Admin. Order</th>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route and Method of Administration</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>Cetuximab</td>
<td>400mg/m²</td>
<td>IV observe post infusion</td>
<td>Over 120mins</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>8,15</td>
<td>Cetuximab</td>
<td>250mg/m²</td>
<td>IV observe post infusion</td>
<td>Over 60mins</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1,8,15</td>
<td>Cetuximab</td>
<td>250mg/m²</td>
<td>IV</td>
<td>Over 60mins</td>
<td>2 onwards</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>CISSplatin</td>
<td>100mg/m²</td>
<td>IV infusion</td>
<td>1000ml 0.9% NaCl over 2 hours</td>
<td>1-6</td>
</tr>
<tr>
<td>3</td>
<td>1-4</td>
<td>5-Fluorouracil</td>
<td>1000mg/m²/day</td>
<td>Continuous IV infusion</td>
<td>1000ml 0.9% NaCl over 22 hours</td>
<td>1-6</td>
</tr>
</tbody>
</table>

*Obtain vital signs pre-infusion, at 1 hr and post-infusion. 1hr observation period following end of 1st and 2nd infusion. If no infusion reaction occurs for 2 consecutive doses, then may discontinue observation period and vital signs.

The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min. The recommended infusion period is 120 minutes.

For the subsequent weekly doses, the recommended infusion period is 60 minutes. The maximum infusion rate must not exceed 10 mg/min. May be administered diluted in 0.9% NaCl or undiluted. Flush the line with 0.9% NaCl at the end of the cetuximab infusion.
**NCCP Chemotherapy Regimen**

*Pre and post hydration therapy required for CISplatin
See local hospital policy recommendations.
Suggested rehydration for CISplatin therapy:
1. Administer 10mmol magnesium sulphate (MgSO₄) (+/-KCl 20mmol/L if indicated) in 1000 mL sodium chloride 0.9% over 60 minutes.
Administer CISplatin as described above

Post hydration: Administer 1000 ml 0.9% NaCl over 60mins

Mannitol 10% may be used to as per local policy to induce diuresis, although there is no conclusive evidence that this is required. The routine use of furosemide to increase urine flow is not recommended unless there is evidence of fluid overload (2,3).

*Alternatively 5-Fluorouracil may be administered at 2000mg/m² over 46-48 hours on day 1 and day 2 and then repeated on day 3 and day 4 for a total dose of 4000mg/m² over 96 hours

### ELIGIBILITY:
- Indication as above
- ECOG status 0-2
- Adequate organ function
- ANC > 1.5 x10⁹ cells/L, platelets 100 x10⁹/L, serum creatinine ≤ 1.5 x ULN, transaminases ≤5 xULN, bilirubin ≤1.5 x ULN

### EXCLUSIONS:
- Hypersensitivity to cetuximab, CISplatin, 5-FU or any of the excipients
- Lactation
- Pre existing neuropathies ≥ grade 2
- Moderate/severe renal impairment (creatinine clearance < 60 mL/min)
- Significant hearing impairment/tinnitus
- Fluorouracil (5-FU) should not be given to patients who are known to be homozygotic for dihydropyrimidine dehydrogenase (DPD) or in patients with a known complete absence of DPD activity.

### PRESCRIPTIVE AUTHORITY:
- The treatment plan must be initiated by a Consultant Medical Oncologist.

### TESTS:

**Baseline tests:**
- FBC
- Renal and hepatic profile (including magnesium)
- ECG (if patient has compromised cardiac function)
- Audiology and creatinine clearance if clinically indicated
- Complete medical history specifically asking about any previous infusion related reactions (IRR) to another antibody, allergy to red meat or tick bites, or any results of tests for IgE antibodies against cetuximab.

**Regular tests:**
- FBC
- Renal and hepatic profile before each cycle (including magnesium)
- Post treatment: monthly electrolytes, magnesium, calcium for 2 months after last cetuximab treatment.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant

Haematological:

Table 1: Dose modification for haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x 10^9/L) (on day of chemotherapy)</th>
<th>Platelets (x 10^9/L) (at any stage during cycle)</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1.5 and ≥100</td>
<td></td>
<td>100% Dose</td>
</tr>
<tr>
<td>0.5 - 1.5 or 50-99</td>
<td></td>
<td>Delay treatment until recovery</td>
</tr>
<tr>
<td>&lt;0.5 or &lt;50</td>
<td></td>
<td>Delay treatment until recovery and consider reducing CISplatin and fluorouracil by 25% for subsequent cycles</td>
</tr>
</tbody>
</table>

Febrile neutropenia

Renal and Hepatic Impairment:

Table 2: Dose modification for renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetuximab</td>
<td>Clinical decision-unlikely to require a reduction</td>
<td>Unlikely to require a dose reduction</td>
</tr>
<tr>
<td>CISplatin</td>
<td>CrCl (ml/min)</td>
<td>Dose</td>
</tr>
<tr>
<td>≥60</td>
<td>100%</td>
<td>No dose reduction necessary</td>
</tr>
<tr>
<td>45-59</td>
<td>75%</td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>Clinical decision. Consider using carboplatin</td>
<td></td>
</tr>
</tbody>
</table>

5-Fluorouracil

Consider dose reduction in severe renal impairment only

<table>
<thead>
<tr>
<th>Bilirubin (micromol/L)</th>
<th>AST</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;85</td>
<td>&lt;180</td>
<td>100%</td>
</tr>
<tr>
<td>&gt;85 or &gt;180</td>
<td></td>
<td>Contraindicated</td>
</tr>
</tbody>
</table>

Clinical decision. Moderate hepatic impairment; reduce initial dose by 1/3. Severe hepatic impairment, reduce initial dose by 1/2. Increase dose if no toxicity
## Non-haematological toxicity

### Table 3: Dose modification schedule for Cetuximab and CISplatin based on adverse events

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adverse reaction</th>
<th>Discontinue</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetuximab</td>
<td>Infusion Reaction Grade 1</td>
<td></td>
<td>Continue slow infusion under close supervision.</td>
</tr>
<tr>
<td></td>
<td>Grade 2</td>
<td></td>
<td>Continue slow infusion and immediately administer treatment for symptoms.</td>
</tr>
<tr>
<td></td>
<td>Grade 3 and 4</td>
<td></td>
<td>Stop infusion immediately, treat symptoms vigorously and contraindicate further use of cetuximab</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>Interstitial lung disease</td>
<td>Discontinue</td>
<td>No dosage adjustment required. See local skin care policy for the prevention and treatment of EGFR-inhibitor adverse skin reactions.</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>Skin reaction grade 1 or 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe skin reaction ≥ grade 3*</td>
<td>First occurrence</td>
<td>Hold cetuximab treatment for a maximum of 2 weeks. Reinitiate therapy only if reaction has resolved to grade 2 at 250mg/m²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second occurrence</td>
<td>Hold cetuximab treatment for a maximum of 2 weeks. Reinitiate therapy only if reaction has resolved to grade 2 at 200mg/m²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Third occurrence</td>
<td>Hold cetuximab treatment for a maximum of 2 weeks. Reinitiate therapy only if reaction has resolved to grade 2 at 150mg/m²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fourth occurrence</td>
<td>Discontinue</td>
</tr>
<tr>
<td>CISplatin</td>
<td>Grade ≥ 2 peripheral neuropathy</td>
<td></td>
<td>Omit CISplatin and consider substituting CISplatin with carboplatin</td>
</tr>
</tbody>
</table>

* See other supportive care section below

## SUPPORTIVE CARE:

### EMETOGENIC POTENTIAL:

- **Cetuximab** Low ([Refer to local policy](http://www.hse.ie/eng/Disclaimer))
- **CISplatin** High ([Refer to local policy](http://www.hse.ie/eng/Disclaimer))
- **5-Fluorouracil** Low ([Refer to local policy](http://www.hse.ie/eng/Disclaimer))
PREMEDICATIONS:

- Patients must receive premedication with an antihistamine and a corticosteroid prior to cetuximab infusion. This premedication is recommended prior to all subsequent infusions. Patient should be educated about the possibility of delayed infusion-related symptoms.
- Hydration prior and post CISplatin administration (Refer local policy) or see recommendations above.

OTHER supportive care:

See local skin care policy for the prevention and treatment of EGFR-inhibitor adverse skin reactions. (Refer to local policy)

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Cetuximab

- **Infusion-related reactions:** The first dose should be administered slowly and the speed must not exceed 5 mg/min whilst all vital signs are closely monitored for at least two hours. If during the first infusion, an infusion-related reaction occurs within the first 15 minutes, the infusion should be stopped. A careful benefit/risk assessment should be undertaken including consideration whether the patient may have preformed IgE antibodies before a subsequent infusion is given.
- If an IRR develops later during the infusion or at a subsequent infusion further management will depend on its severity (Ref Table 3)
- In cases of mild or moderate infusion-related reaction, the infusion rate may be decreased and maintained at the lower rate in all subsequent infusions.
- Severe infusion-related reactions may occur with symptoms usually occurring during the first infusion and up to 1 hour after the end of the infusion. They may occur several hours after or with subsequent infusions. Patients should be warned of the possibility of such a late onset and instructed to contact their physician if symptoms occur
- Occurrence of a severe infusion-related reaction requires immediate and permanent discontinuation of cetuximab therapy and may necessitate emergency treatment.
- Special attention is recommended for patients with reduced performance status and pre-existing cardio-pulmonary disease.
- **Respiratory disorders:** Interstitial lung disease has been observed with EGFR inhibitors. Treatment should be withheld in the event of onset or worsening respiratory symptoms. If pneumonitis or lung infiltrates are confirmed, treatment should be discontinued.
- **Cardiovascular:** An increased frequency of severe and sometimes fatal cardiovascular events and treatment emergent deaths has been observed. When prescribing cetuximab, the cardiovascular and performance status of the patients and concomitant administration of cardiotoxic compounds such as fluoropyrimidines should be taken into account.
- **Skin reactions:** This is the main adverse reaction of cetuximab. Refer to local policy for skin care regime and to Table 3 under Dose Modifications for management of treatment if patient experiences skin reactions.
- **Electrolyte disturbances:** Hypomagnesaemia, hypokalaemia or hypocalcaemia may occur. Electrolyte repletion is recommended, as appropriate.
- **Neutropenia:** Increased risk of severe neutropenia in patients who receive cetuximab in
combination with platinum-based chemotherapy, which may lead to subsequent infectious complications such as febrile neutropenia, pneumonia or sepsis.

CiSplatin
- Renal toxicity: Renal toxicity is common with CiSplatin. Encourage oral hydration.
- Ototoxicity and sensory neural damage should be assessed by history prior to each cycle.

5-Fluorouracil
- Myocardial ischaemia and angina: Cardiotoxicity is a serious complication during treatment with fluorouracil. Patients, especially those with a prior history of cardiac disease or other risk factors, treated with fluorouracil, should be carefully monitored during therapy.
- Dihydropyrimidine dehydrogenase (DPD) deficiency: Rare, life-threatening toxicities such as stomatitis, mucositis, neutropenia, neurotoxicity and diarrhoea have been reported following administration of fluoropyrimidines (e.g. fluorouracil and capecitabine). Severe unexplained toxicities require investigation prior to continuing with treatment.

DRUG INTERACTIONS:
- Avoid concurrent use of CiSplatin with nephrotoxic or ototoxic drugs (e.g. aminoglycosides, furosemide, NSAIDS) due to additive toxicity. If necessary monitor renal function closely.
- Marked elevations of prothrombin time and INR have been reported in patients stabilized on warfarin therapy following initiation of fluorouracil regimes.
- Concurrent administration of fluorouracil and phenytoin may result in increased serum levels of phenytoin.
- Fluorouracil (5-FU) is contraindicated in combination with brivudin, sorivudin and analogues as these are potent inhibitors of the 5-FU-metabolising enzyme dihydropyrimidine dehydrogenase (DPD).
- Current drug interaction databases should be consulted for more information.

ATC CODE:
- Cetuximab - L01XC06
- CiSplatin - L01XA01
- 5-Fluorouracil - L01BC02

REFERENCES:
NCCP Chemotherapy Regimen


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>08/05/2017</td>
<td></td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>2</td>
<td>09/01/2019</td>
<td>Standardisation of treatment table. Updated with revised CISplatin hydration regimen recommendations,</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>3</td>
<td>16/05/2019</td>
<td>Update of exclusion criteria, emetogenic potential, tests, and drug interactions, hepatic dose modifications</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>4</td>
<td>09/10/2019</td>
<td>Update of exclusion criteria</td>
<td>Prof Maccon Keane</td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

1 ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes
Further details on the Cancer Drug Management Programme is available at: http://www.hse.ie/eng/services/list/5/cancer/proinfo/medonc/cdmp/

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens